| Literature DB >> 27484348 |
Adesuwa Olomu1, William Hart-Davidson2, Zhehui Luo3, Karen Kelly-Blake4, Margaret Holmes-Rovner4.
Abstract
BACKGROUND: Use of Shared Decision-Making (SDM) and Decision Aids (DAs) has been encouraged but is not regularly implemented in primary care. The Office-Guidelines Applied to Practice (Office-GAP) intervention is an application of a previous model revised to address guidelines based care for low-income populations with diabetes and coronary heart disease (CHD).Entities:
Keywords: Federally qualified health center; Patient activation; Prevention of heart disease; Quality improvement; Shared decision-making
Mesh:
Year: 2016 PMID: 27484348 PMCID: PMC4970246 DOI: 10.1186/s12913-016-1603-3
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Office-GAP model
Elements of relational coordination of shared decision making implemented in Office-GAP
| High quality | ||
|---|---|---|
| Communication is… | Office GAP Program element | Measured by |
| Frequent | Office visits w/GAP checklist | Use of checklist |
| Accurate | Decision support tools | Use of ADA/ACPaand Health Dialog decision Aidsb |
| Problem solving | Self-management programs; | Referrals to community programb |
| Group visit, checklist | Observation/Interviewb | |
| Provider-Patient | ||
| Relationships include… | ||
| Shared goals | Checklist | COMRADE39 |
| Shared knowledge | Decision support tools | Signed copies by patient and provider |
| Mutual respect | Group visit checklist form | COMRADE39 |
| Patient-Provider | ||
| Relationships result in… | ||
| Enhanced understanding of | “Here’s where we are today” | Use of checklist |
| Pros and cons of treatments | ||
| Confidence in care plan | “We are on the right track” | COMRADE39 |
aADA/ACP: American Diabetic Association/American College of Physician
bData available upon request
COMRADE combined outcome measure for risk communication and treatment decision making
Demographics and baseline characteristics (N = 95)
| Continuous variable | Mean | SD |
|---|---|---|
| Age (years) | 53.2 | 10.3 |
| Body mass index (BMI, kg/m2) | 36.9 | 10.2 |
| Charlson Index* | 2.6 | 1.5 |
| Total No. of Office-GAP visits completed | 2.4 | 0.8 |
| Discrete variable |
| % |
| Female | 51 | 53.7 |
| Race | ||
| White | 49 | 51.6 |
| African American | 35 | 36.8 |
| Other race/ethnicity | 11 | 11.6 |
| Education | ||
| Less than high school | 30 | 31.6 |
| HS diploma or higher | 65 | 68.4 |
| Primary insurance | ||
| Medicaid or dual | 21 | 22.1 |
| Medicare | 29 | 30.5 |
| Other | 37 | 39.0 |
| Uninsured | 8 | 8.4 |
| Smoking status | ||
| Current smoker | 38 | 40.0 |
| Ex-smoker | 13 | 13.7 |
| Non-smoker | 44 | 46.3 |
| BMI Category | ||
| < 30 | 21 | 22.1 |
| 30–35 | 23 | 24.2 |
| > 35 | 51 | 53.7 |
| Office-GAP visit patterns | ||
| Patients completed only 1 visit | 18 | 19.0 |
| Only 2 visits | 17 | 17.9 |
| All 3 visits | 60 | 63.2 |
| Past Medical History* | ||
| Hypertension | 76 | 89.4 |
| Diabetes | 70 | 82.4 |
| Dyslipidemia (hyperlipidemia) | 65 | 76.5 |
| Chronic pulmonary disease | 19 | 22.4 |
| Peripheral vascular disease | 18 | 21.2 |
| Myocardial infarction | 13 | 15.3 |
| Angina | 10 | 11.8 |
| Cerebrovascular disease | 9 | 10.6 |
| Congestive heart failure | 8 | 9.4 |
| Connective tissue disease | 4 | 4.7 |
| Peptic ulcer | 8 | 9.4 |
| Liver disease | 2 | 2.4 |
| Dementia | 0 | 0 |
| Diabetics with end organ damage | 25 | 29.4 |
| Renal failure | 4 | 4.7 |
| Any tumor | 7 | 8.2 |
| AIDS/Metastatic solid tumor/Leukemia/lymphoma | 0 | 0 |
*% for Past medical history and Charlson index are based on 85 patients with chart review
Hierarchical linear models for COMRADE subscale scores
| Satisfaction | Confidence | |
|---|---|---|
| 3 months | 4.55*** | 3.70** |
| [2.63, 6.46] | [1.33, 6.07] | |
| 6 months | 5.03*** | 5.48*** |
| [3.09, 6.97] | [2.96, 8.00] | |
| Age | 0.10 | 0.06 |
| [−0.04, 0.24] | [−0.09, 0.22] | |
| Black | −1.07 | −0.76 |
| [−4.03, 1.88] | [−4.02, 2.50] | |
| Female | −0.61 | −0.84 |
| [−3.37, 2.16] | [−3.90, 2.21] | |
| Medicaid | −1.72 | −1.92 |
| [−5.54, 2.09] | [−6.15, 2.32] | |
| Medicare | −0.13 | −0.18 |
| [−3.44, 3.18] | [−3.82, 3.47] | |
| Charlson index | −1.36** | −1.18* |
| [−2.34, −0.38] | [−2.25, −0.10] | |
| Intercept | 39.72*** | 39.32*** |
| [36.74, 42.70] | [35.97, 42.67] | |
| N Obs. | 205 | 205 |
Reference groups are: Pre-GAP; male; white or other race; other insurance or uninsured. Age and Charlson index are centered at the means
COMRADE combined outcome measure for risk communication and treatment decision making
*p < 0.05, **p < 0.01, ***p < 0.001
Odds ratio [95 % CI] for medication use over time
| (1) | (2) | (3) | (4) | (5) | |
|---|---|---|---|---|---|
| Aspirin/Plavix | Statin | ACEI/ABR | Beta-blocker | “Global” medication adherence | |
| 3 months | 1.50* | 1.12* | 1.21 | 1.31 | 1.19 |
| [1.05, 2.15] | [1.00, 1.25] | [0.84, 1.75] | [0.91, 1.89] | [0.85, 1.66] | |
| 6 months | 1.92** | 1.34 | 1.38 | 1.75* | 1.52* |
| [1.27, 2.92] | [0.99, 1.81] | [0.92, 2.09] | [1.07, 2.85] | [1.01, 2.29] | |
| 12 months | 1.81** | 1.52* | 1.13 | 1.75* | 1.34 |
| [1.17, 2.79] | [1.07, 2.16] | [0.72, 1.78] | [1.07, 2.85] | [0.87, 2.06] | |
| Age | 1.02 | 0.99 | 1.03 | 0.99 | 1.03 |
| [0.98, 1.06] | [0.94, 1.04] | [0.98, 1.08] | [0.93, 1.06] | [0.99, 1.08] | |
| Black | 0.90 | 1.16 | 0.90 | 0.43 | 0.87 |
| [0.36, 2.22] | [0.43, 3.08] | [0.36, 2.28] | [0.10, 1.84] | [0.35, 2.13] | |
| Female | 1.27 | 2.06 | 0.77 | 0.77 | 0.72 |
| [0.54, 2.97] | [0.83, 5.07] | [0.31, 1.89] | [0.19, 3.10] | [0.30, 1.70] | |
| Medicaid | 0.35 | 2.75 | 0.56 | 0.36 | 0.46 |
| [0.11, 1.07] | [0.80, 9.38] | [0.17, 1.81] | [0.07, 1.95] | [0.15, 1.38] | |
| Medicare | 0.96 | 2.16 | 0.71 | 0.70 | 0.74 |
| [0.34, 2.72] | [0.73, 6.40] | [0.24, 2.05] | [0.11, 4.68] | [0.26, 2.10] | |
| Charlson index | 1.16 | 1.03 | 0.83 | 1.09 | 0.83 |
| [0.85, 1.59] | [0.74, 1.42] | [0.61, 1.13] | [0.70, 1.71] | [0.61,1.12] | |
| N obs. | 300 | 316 | 296 | 132 | 332 |
OR with 95 % confidence intervals in brackets
Reference groups are: Pre-GAP; male; white or other race; other insurance or uninsured, Age and Charlson index centered at their respective means (53.5 and 2.7)
*p < 0.05, **p < 0.01
Fig. 2Global medication adherence
Medication eligibility criteria. Eligibility criteria for prescribing medication to appropriate patient
| Variable | Eligibility criteria |
|---|---|
| Aspirin/Plavix | Diagnosed with (1) coronary artery disease, (2) peripheral vascular disease, or (3) diabetes mellitus combined with one other risk factor (for males’ age > 50, or for females’ age > 60). |
| Beta-blockers | Diagnosed with (1) angina, (2) congestive heart failure paired with left ventricular systolic dysfunction, (3) coronary artery disease, (4) myocardial infarction, or (5) peripheral vascular disease. |
| ACEI/ARB | Diagnosed with either (1) congestive heart failure paired with an ejection fraction < 40, or (2) diabetes mellitus. |
| Statins & other lipid-lowering agents | Diagnosed with (1) diabetes mellitus, (2) coronary artery disease, (3) hyperlipidemia, or (4) peripheral vascular disease. |
TIDieR checklist. Template for intervention description and replication checklist
| Item number | Item | Location | |
|---|---|---|---|
| Primary paper | Other details | ||
| 1 | Brief name: Provide the name of a phrase that describes the intervention. | Page 1 | Office-GAP intervention |
| 2 | Why: Describe any rationale, theory, or goal of the elements essential to the intervention | Page 6 | Introduction |
| 3 | Materials: Describe any physical or informational materials used in the intervention, including those provided to participants or used in intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed (e.g., online appendix, URL). | Page 12, 13 | Patient and provider intervention |
| 4 | Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, including any enabling or support activities. | Page 13, 14 | Group visit and clinic visit |
| 5 | Who Provided: For each category of intervention provider (e.g., psychologist, nursing assistant), describe their expertise, background and any specific training given. | Page 10, 14 | Family Physician, Internal medicine Physician, Nurse Practitioner, Research Assistant |
| 6 | How: Describe the modes of delivery (e.g., face-to-face or by some other mechanism, such as internet or telephone) of the intervention and whether it was provided individually or in a group. | Page 13, 14 | Face-to-face group visit |
| 7 | Where: Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or relevant features. | Page 9 | Group visit and clinic |
| 8 | When and How Much: Describe the number of times the intervention was delivered and over what period of time including the number of sessions, their schedule, and their duration, intensity or dose. | Page 13 | Patient intervention, group visits, and 2 follow up visits |
| 9 | Tailoring: If the intervention was planned to be personalized, titrated or adapted, then describe what, why, when, and how. | N/A | Intervention was not personalized, titrated, or adapted |
| 10 | Modifications: If the intervention was modified during the course of the study, describe the changes (what, why, when, and how). | N/A | |
| 11 | Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them. | Page 14, 15 | Intervention feasibility |
| 12 | Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned. | Page 17, 18 | Intervention feasibility and program fidelity |